Updates in the Treatment of Relapsed or Refractory Marginal Zone Lymphoma : Episode 1

Updates in the Treatment of Relapsed or Refractory Marginal Zone Lymphoma

November 17, 2021

Article

This publication reviews the role of Bruton tyrosine kinase inhibitors and PI3K inhibitors, particularly in the relapsed or refractory setting, for the treatment of marginal zone lymphoma, recapping key insights from a scientific interchange & workshop.

EP: 1.Updates in the Treatment of Relapsed or Refractory Marginal Zone Lymphoma

EP: 2.The Evolving Therapeutic Landscape for Marginal Zone Lymphoma: Expert Perspectives

Related Content

The Evolving Therapeutic Landscape for Marginal Zone Lymphoma: Expert Perspectives

The Evolving Therapeutic Landscape for Marginal Zone Lymphoma: Expert Perspectives

November 17th 2021

Related Content

The Evolving Therapeutic Landscape for Marginal Zone Lymphoma: Expert Perspectives

The Evolving Therapeutic Landscape for Marginal Zone Lymphoma: Expert Perspectives

November 17th 2021

Latest Conference Coverage

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.